308 related articles for article (PubMed ID: 9865687)
21. Future perspectives of docetaxel (Taxotere) in front-line therapy.
Piccart MJ; Di Leo A
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
[TBL] [Abstract][Full Text] [Related]
22. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
[TBL] [Abstract][Full Text] [Related]
23. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: from metastatic to adjuvant setting.
Nabholtz JM; Tonkin K; Smylie M; Mackey J; Janowska-Wieczorek A
Semin Oncol; 1999 Feb; 26(1 Suppl 3):10-6. PubMed ID: 10203265
[TBL] [Abstract][Full Text] [Related]
24. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
25. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
Dieras V
Semin Oncol; 1998 Oct; 25(5 Suppl 12):18-22. PubMed ID: 9865707
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin.
Colombo T; Parisi I; Zucchetti M; Sessa C; Goldhirsch A; D'Incalci M
Ann Oncol; 1999 Apr; 10(4):391-5. PubMed ID: 10370780
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Aapro M
Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer.
Miller VA; Kris MG
Semin Oncol; 2000 Apr; 27(2 Suppl 3):3-10. PubMed ID: 10810932
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart.
Platel D; Pouna P; Bonoron-Adèle S; Robert J
Toxicol Appl Pharmacol; 2000 Mar; 163(2):135-40. PubMed ID: 10698671
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel in breast cancer and a rationale for combination therapy.
Hortobágyi G
Oncology (Williston Park); 1997 Jun; 11(6 Suppl 6):11-5. PubMed ID: 9213321
[TBL] [Abstract][Full Text] [Related]
32. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Valero V; Perez E; Dieras V
Semin Oncol; 2001 Aug; 28(4 Suppl 12):15-23. PubMed ID: 11552226
[TBL] [Abstract][Full Text] [Related]
33. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
[TBL] [Abstract][Full Text] [Related]
34. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients.
Ekholm E; Rantanen V; Bergman M; Vesalainen R; Antila K; Salminen E
Anticancer Res; 2000; 20(3B):2045-8. PubMed ID: 10928149
[TBL] [Abstract][Full Text] [Related]
36. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
Granda TG; Filipski E; D'Attino RM; Vrignaud P; Anjo A; Bissery MC; Lévi F
Cancer Res; 2001 Mar; 61(5):1996-2001. PubMed ID: 11280758
[TBL] [Abstract][Full Text] [Related]
37. [Docetaxel hydrate for treatment of advanced breast cancers].
Fujii H
Nihon Rinsho; 2000 Apr; 58 Suppl():254-8. PubMed ID: 11026003
[No Abstract] [Full Text] [Related]
38. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Nabholtz JM; Crown J
Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
[TBL] [Abstract][Full Text] [Related]
39. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Radaideh SM; Sledge GW
Breast Cancer Res Treat; 2008 Sep; 111(2):203-8. PubMed ID: 17990102
[TBL] [Abstract][Full Text] [Related]
40. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel.
Briasoulis E; Karavasilis V; Tzamakou E; Rammou D; Soulti K; Piperidou C; Pavlidis N
Cancer Chemother Pharmacol; 2004 May; 53(5):452-7. PubMed ID: 14749894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
